KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Inventory (2018 - 2025)

Rigel Pharmaceuticals has reported Inventory over the past 8 years, most recently at $11.5 million for Q4 2025.

  • For Q4 2025, Inventory rose 91.7% year-over-year to $11.5 million; the TTM value through Dec 2025 reached $11.5 million, up 91.7%, while the annual FY2025 figure was $11.5 million, 91.7% up from the prior year.
  • Inventory for Q4 2025 was $11.5 million at Rigel Pharmaceuticals, down from $13.3 million in the prior quarter.
  • Over five years, Inventory peaked at $13.3 million in Q3 2025 and troughed at $4.7 million in Q1 2025.
  • A 5-year average of $7.8 million and a median of $6.9 million in 2021 define the central range for Inventory.
  • Biggest five-year swings in Inventory: surged 328.3% in 2021 and later plummeted 40.61% in 2024.
  • Year by year, Inventory stood at $6.6 million in 2021, then surged by 37.82% to $9.1 million in 2022, then crashed by 39.44% to $5.5 million in 2023, then grew by 8.69% to $6.0 million in 2024, then soared by 91.7% to $11.5 million in 2025.
  • Business Quant data shows Inventory for RIGL at $11.5 million in Q4 2025, $13.3 million in Q3 2025, and $10.4 million in Q2 2025.